STROBE Statement-checklist of items that should be included in reports of observational studies

| Section/item | Item No | Recommendation | Reported on Page Number/Line Number | Reported on Section/Paragraph |
| :---: | :---: | :---: | :---: | :---: |
| Title and abstract | 1 | (a) Indicate the study's design with a commonly used term in the title or the abstract | Page 21 i ne15 | Net hods- abstr act |
|  |  | (b) Provide in the abstract an informative and balanced summary of what was done and what was found | Page 21 l ne18 28 | Nethods- resul ts |
| Introduction |  |  |  |  |
| Background/ rationale | 2 | Explain the scientific background and rationale for the investigation being reported | Page 35 | Introduction |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses | Page 61 i ne6-15 | Intr oduction |
| Methods |  |  |  |  |
| Study design | 4 | Present key elements of study design early in the paper | Page 61 ine18 24 | Ivelinuus- su uuy rupui da on |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | Page 61 l ne15-30 | Net hods- St udy Popul at i on |
| Participants | 6 | (a) Cohort study-Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <br> Case-control study-Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <br> Cross-sectional study-Give the eligibility criteria, and the sources and methods of selection of participants | Page 61 l ne18 30 | Net hods- St udy Popul at i on |
|  |  | (b) Cohort study -For matched studies, give matching criteria and number of exposed and unexposed Case-control study-For matched studies, give matching criteria and the number of controls per case | Page 61 l ne18 30 | Net hods- St udy Popul at i on |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | Page 61 l ne18 30 | Net hods- St udy Popul at i on |
| Data sources/ measurement | $8^{*}$ | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | Page 7 l i ne6-17 | Net hods- Senen anal ysis |
| Bias | 9 | Describe any efforts to address potential sources of bias | Page 89 | Net hods- Stati stical an |
| Study size | 10 | Explain how the study size was arrived at | Page 89 |  |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | Page 89 | Methods- Statistical an al ysi s |


| Statistical methods | 12 | (a) Describe all statistical methods, including those used to control for confounding | Page 89 |  |
| :---: | :---: | :---: | :---: | :---: |
|  |  | (b) Describe any methods used to examine subgroups and interactions | Page 89 |  |
|  |  | (c) Explain how missing data were addressed | Page 8-9 |  |
|  |  | (d) Cohort study-If applicable, explain how loss to follow-up was addressed <br> Case-control study-If applicable, explain how matching of cases and controls was addressed Cross-sectional study-If applicable, describe analytical methods taking account of sampling strategy | Page 89 | Net hods- Statistical an al ysi s |
|  |  | (e) Describe any sensitivity analyses | Page 8-9 |  |
| Results |  |  |  |  |
| Participants | 13* | (a) Report numbers of individuals at each stage of study-eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | Page 9 line 7-12 | Resul ts- Tabl e 1 |
|  |  | (b) Give reasons for non-participation at each stage | N/A | N/A |
|  |  | (c) Consider use of a flow diagram | N/A | N/A |
| Descriptive data | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders | Page 9 line 7-12 | Resul ts- Table 1 |
|  |  | (b) Indicate number of participants with missing data for each variable of interest | N/A | N/A |
|  |  | (c) Cohort study-Summarise follow-up time (eg, average and total amount) | N/A | N/A |
| Outcome data | 15* | Cohort study-Report numbers of outcome events or summary measures over time | Page 9 I i ne 7-12 | Resul ts- Table 1 |
|  |  | Case-control study-Report numbers in each exposure category, or summary measures of exposure | N/A | N/A |
|  |  | Cross-sectional study-Report numbers of outcome events or summary measures | N/A | N/A |
| Main results | 16 | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95\% confidence interval). Make clear which confounders were adjusted for and why they were included | Page 9-10 | Resul ts- Table 34 |
|  |  | (b) Report category boundaries when continuous variables were categorized | Page 10 I ine 6-11 | Results- Table s2 |
|  |  | (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | Page 10 line 6-11 | Results- Table s2 |
| Other analyses | 17 | Report other analyses done-eg analyses of subgroups and interactions, and sensitivity analyses | Page 10 I i ne 6-11 | Results- Table s2 |
| Discussion |  |  |  |  |
| Key results | 18 | Summarise key results with reference to study objectives | Page 10 I ine 1318 | Di scussi on- first parag |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | Page 11 line 1828 | Di scussi on-fifth parag raph |


| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | Page 11 line 1828 | Di scussi on-fifth par ag raph |
| :---: | :---: | :---: | :---: | :---: |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results | Page 11 I i ne 12-17 | Di scussi on- fourth para |
| Other information |  |  |  |  |
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | Page 1 I i ne 29-30 | Page 1 I i ne 29-30 |

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE
 annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

[^0]
[^0]:    Article information: https://dx.doi.org/10.21037/tau-23-395
    *As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.

